Abstract
A novel non-activating CD28-specific monovalent single-chain variable region antibody fragment (scFv Ab) blocks CD28 while leaving the tolerogenic CTLA4-B7 interactions unopposed. Here we explore its utility as part of a tolerance induction strategy.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have